keyword
MENU ▼
Read by QxMD icon Read
search

Fallopian tube cancer

keyword
https://www.readbyqxmd.com/read/27920138/culprit-or-bystander-the-role-of-the-fallopian-tube-in-ovarian-high-grade-serous-carcinoma
#1
Elizabeth M Swisher, Rochelle L Garcia, Mark R Kilgore, Barbara M Norquist
The concurrence of intraepithelial high-grade neoplasia in the fallopian tube with metastatic implants has been taken as evidence of a tubal origin for high-grade serous pelvic carcinomas. In the current issue, Eckert and colleagues perform detailed genomic phylogenetic analyses and demonstrate that some cases of high-grade serous intraepithelial tubal neoplasia are metastatic implants and not precursor lesions. Cancer Discov; 6(12); 1309-11. ©2016 AACR.See related article by Eckert and colleagues, p. 1342...
December 2016: Cancer Discovery
https://www.readbyqxmd.com/read/27914240/hysterectomies-in-portugal-2000-2014-what-has-changed
#2
Inês Gante, Cláudia Medeiros-Borges, Fernanda Águas
OBJECTIVE: To describe conditions regarding hysterectomies during the past 15 years in Portugal. STUDY DESIGN: Nationwide retrospective study of women who underwent hysterectomy in Portuguese public hospitals in the period between 2000 and 2014. Patient data regarding hospital codes, geography, patient age, indications, operative techniques, associated procedures, complications, admission dates, discharge dates and 30-day postoperative readmissions were extracted from the national database with information regarding all public hospitals in Portugal...
November 21, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27898521/pathogenesis-and-heterogeneity-of-ovarian-cancer
#3
Paul T Kroeger, Ronny Drapkin
PURPOSE OF REVIEW: The most common type of ovarian cancer, high-grade serous ovarian carcinoma (HGSOC), was originally thought to develop from the ovarian surface epithelium. However, recent data suggest that the cells that undergo neoplastic transformation and give rise to the majority of HGSOC are from the fallopian tube. This development has impacted both translational research and clinical practice, revealing new opportunities for early detection, prevention, and treatment of ovarian cancer...
November 26, 2016: Current Opinion in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/27884207/potential-contribution-of-the-uterine-microbiome-in-the-development-of-endometrial-cancer
#4
Marina R S Walther-António, Jun Chen, Francesco Multinu, Alexis Hokenstad, Tammy J Distad, E Heidi Cheek, Gary L Keeney, Douglas J Creedon, Heidi Nelson, Andrea Mariani, Nicholas Chia
BACKGROUND: Endometrial cancer studies have led to a number of well-defined but mechanistically unconnected genetic and environmental risk factors. One of the emerging modulators between environmental triggers and genetic expression is the microbiome. We set out to inquire about the composition of the uterine microbiome and its putative role in endometrial cancer. METHODS: We undertook a study of the microbiome in samples taken from different locations along the female reproductive tract in patients with endometrial cancer (n = 17), patients with endometrial hyperplasia (endometrial cancer precursor, n = 4), and patients afflicted with benign uterine conditions (n = 10)...
November 25, 2016: Genome Medicine
https://www.readbyqxmd.com/read/27882232/metastatic-gastric-cancer-to-the-female-genital-tract
#5
Hiroshi Matsushita, Kazushi Watanabe, Akihiko Wakatsuki
Metastases to the female genital tract from gastric cancer are rare, but they significantly worsen the prognosis of such patients. The potential routes for metastasis to the female genital tract from gastric cancer include hematogenous spread, lymphatic spread and surface implantation. The rate of lymphatic metastasis to the ovary from gastric cancer has been reported to be higher compared with that from colorectal cancer. Uterine or Fallopian tube metastases are usually secondary to ovarian metastases, which are typically identified prior to the detection of gastric cancer in half of all synchronous cases, with complaints of abdominal distention, pain, palpable mass, or abnormal uterine bleeding...
November 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27870706/evaluation-of-a-validated-biomarker-test-in-combination-with-a-symptom-index-to-predict-ovarian-malignancy
#6
Renata R Urban, Alan Smith, Kathy Agnew, Vinicius Bonato, Barbara A Goff
OBJECTIVE: This study aimed to evaluate the predictive ability of a multivariate biomarker test in combination with a symptom index (SI) to identify ovarian cancer in a cohort of women planning to undergo surgery for a pelvic mass. METHODS: This was a prospective study of patients seen at a tertiary care medical center. Following consent, patients completed an SI and preoperative serum was collected for a Food and Drug Administration-cleared multivariate biomarker test [multivariate index assay (MIA)]...
November 17, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27869446/-oncopathological-aspects-of-brca1-and-brca2-genes-inactivation-in-tumors-of-ovary-fallopian-tube-and-pelvic-peritoneum
#7
Petr Škapa, Pavel Dundr
Ovarian carcinoma represents a heterogeneous group of malignant epithelial tumors which could be divided into two fundamental groups: Type I (endometrioid carcinoma, clear cell carcinoma, low grade serous carcinoma, mucinous carcinoma and more rare seromucinous carcinoma and malignant Brenner tumor) and type II (high grade serous carcinoma - HGSC). HGSC is the most frequent ovarian carcinoma which may be etiologically linked to inactivation of tumor suppressor genes BRCA1/2 and TP53 and differs from type I carcinomas by higher aggressiveness, tendency to peritoneal spread and worse prognosis...
2016: Ceskoslovenská Patologie
https://www.readbyqxmd.com/read/27858363/orthotopic-model-of-ovarian-cancer
#8
Alessandra Decio, Raffaella Giavazzi
Epithelial ovarian cancer (EOC) is the fifth commonest cancer-related cause of female death in the developed world. In spite of current surgical and chemotherapeutic options the vast majority of patients have widely metastatic disease and the survival rate has not much changed over the last years. The anti-angiogenic drugs are driving the field of agents targeting the tumor microenvironment in ovarian cancer. Preclinical models that accurately reproduce the molecular and biological features of ovarian cancer patients are a valuable means of producing reliable data on personalized medicine and predicting the therapeutic response in clinical trials...
2016: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27856443/genomics-of-ovarian-cancer-progression-reveals-diverse-metastatic-trajectories-including-intraepithelial-metastasis-to-the-fallopian-tube
#9
Mark A Eckert, Shawn Pan, Kyle M Hernandez, Rachel M Loth, Jorge Andrade, Samuel L Volchenboum, Pieter Faber, Anthony Montag, Ricardo Lastra, Marcus E Peter, S Diane Yamada, Ernst Lengyel
: Accumulating evidence has supported the fallopian tube rather than the ovary as the origin for high-grade serous ovarian cancer (HGSOC). To understand the relationship between putative precursor lesions and metastatic tumors, we performed whole-exome sequencing on specimens from eight HGSOC patient progression series consisting of serous tubal intraepithelial carcinomas (STIC), invasive fallopian tube lesions, invasive ovarian lesions, and omental metastases. Integration of copy number and somatic mutations revealed patient-specific patterns with similar mutational signatures and copy-number variation profiles across all anatomic sites, suggesting that genomic instability is an early event in HGSOC...
December 2016: Cancer Discovery
https://www.readbyqxmd.com/read/27842573/pseudocarcinomatous-hyperplasia-of-the-fallopian-tube-mimicking-tubal-cancer-a-radiological-and-pathological-diagnostic-challenge
#10
Nam Kyung Lee, Kyung Un Choi, Ga Jin Han, Byung Su Kwon, Yong Jung Song, Dong Soo Suh, Ki Hyung Kim
BACKGROUND: Pseudocarcinomatous hyperplasia of the fallopian tube is a rare, benign disease characterized by florid epithelial hyperplasia. CASE PRESENTATION: The authors present the history and details of a 22-year-old woman with bilateral pelvic masses and a highly elevated serum CA-125 level (1,056 U/ml). Ultrasonography and magnetic resonance imaging (MRI) of the pelvis showed bilateral adnexal complex cystic masses with a fusiform or sausage-like shape. Contrast-enhanced fat-suppressed T1-weighted images showed enhancement of papillary projections of the right adnexal mass and enhancement of an irregular thick wall on the left adnexal mass, suggestive of tubal cancer...
November 14, 2016: Journal of Ovarian Research
https://www.readbyqxmd.com/read/27822089/danish-gynecological-cancer-database
#11
REVIEW
Sarah Mejer Sørensen, Signe Frahm Bjørn, Kirsten Marie Jochumsen, Pernille Tine Jensen, Ingrid Regitze Thranov, Helle Hare-Bruun, Lene Seibæk, Claus Høgdall
AIM OF DATABASE: The Danish Gynecological Cancer Database (DGCD) is a nationwide clinical cancer database and its aim is to monitor the treatment quality of Danish gynecological cancer patients, and to generate data for scientific purposes. DGCD also records detailed data on the diagnostic measures for gynecological cancer. STUDY POPULATION: DGCD was initiated January 1, 2005, and includes all patients treated at Danish hospitals for cancer of the ovaries, peritoneum, fallopian tubes, cervix, vulva, vagina, and uterus, including rare histological types...
2016: Clinical Epidemiology
https://www.readbyqxmd.com/read/27821315/current-perspectives-on-recommendations-for-brca-genetic-testing-in-ovarian-cancer-patients
#12
Ignace Vergote, Susana Banerjee, Anne-Marie Gerdes, Christi van Asperen, Christian Marth, Fatima Vaz, Isabelle Ray-Coquard, Dominique Stoppa-Lyonnet, Antonio Gonzalez-Martin, Jalid Sehouli, Nicoletta Colombo
Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now recognised risk of ovarian cancer (OC) patients, even those with no known family history, harbouring a mutation in BRCA1/2, together with the first poly adenosine diphosphate ribose polymerase inhibitor (PARPi; olaparib [Lynparza]) being licenced for the treatment of BRCA-mutated OC, has led to reconsideration of referral criteria for OC patients...
December 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27817932/population-based-study-of-survival-for-women-with-serous-cancer-of-the-ovary-fallopian-tube-peritoneum-or-undesignated-origin-on-behalf-of-the-swedish-gynecological-cancer-group-swegcg
#13
Pernilla Dahm-Kähler, Christer Borgfeldt, Erik Holmberg, Christian Staf, Henrik Falconer, Maria Bjurberg, Preben Kjölhede, Per Rosenberg, Karin Stålberg, Thomas Högberg, Elisabeth Åvall-Lundqvist
OBJECTIVE: The aim of the study was to determine survival outcome in patients with serous cancer in the ovary, fallopian tube, peritoneum and of undesignated origin. METHODS: Nation-wide population-based study of women≥18years with histologically verified non-uterine serous cancer, included in the Swedish Quality Registry for primary cancer of the ovary, fallopian tube and peritoneum diagnosed 2009-2013. Relative survival (RS) was estimated using the Ederer II method...
November 3, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27810554/the-performance-and-safety-of-bilateral-salpingectomy-for-ovarian-cancer-prevention-in-the-united-states
#14
Gillian Elizabeth Hanley, Jessica Nell McAlpine, Celeste Leigh Pearce, Dianne Miller
BACKGROUND: Ovarian cancer is the leading cause of death due to gynecologic malignancy and the fifth most common cause of cancer deaths in developed countries. Recent evidence has indicated that the most common and lethal form of ovarian cancer originates in the distal fallopian tube, and recommendations for surgical removal of the fallopian tube (bilateral salpingectomy) at the time of other gynecologic surgeries (particularly hysterectomy and tubal sterilization) have been made, most recently by the American Congress of Obstetricians and Gynecologists...
November 1, 2016: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27809878/synuclein-%C3%AE-sncg-expression-in-ovarian-cancer-is-associated-with-high-risk-clinicopathologic-disease
#15
Anna Strohl, Kristina Mori, Stacey Akers, Wiam Bshara, Barbara Buttin, Peter J Frederick, Irene B Helenowski, Carl D Morrison, Kunle Odunsi, Julian C Schink, Denise M Scholtens, Jian-Jun Wei, J Julie Kim
BACKGROUND: Synuclein gamma (SNCG) expression is associated with advanced disease and chemoresistance in multiple solid tumors. Our goal was to determine if SNCG protein expression in ovarian cancer was correlated with clinicopathologic variables and patient outcomes. METHODS: Tissue microarrays from primary tumors of 357 ovarian, fallopian tube, and primary peritoneal cancer patients, who underwent primary surgery at Roswell Park Cancer Institute between 1995 and 2007, were immunohistochemically stained for SNCG...
November 3, 2016: Journal of Ovarian Research
https://www.readbyqxmd.com/read/27807494/ovarian-carcinosarcoma-and-its-association-with-mature-cystic-teratoma-and-primary-tubal-carcinoma
#16
Sunida Rewsuwan, Nopporn Satabongkoch, Prapaporn Suprasert, Surapan Khunamornpong
Introduction. Carcinosarcoma is an uncommon form of ovarian cancers, classified as being part of the group of mixed epithelial and mesenchymal tumors. The occurrence of carcinosarcoma in association with a mature cystic teratoma and synchronous tubal carcinoma is very rare. Case Report. A 69-year-old woman presented with a pelvic mass. An abdominal computerized tomographic scan detected a 15 cm right pelvic mass which was suggestive of malignant transformation of a dermoid cyst. Intraoperative, bilateral ovarian masses (left 10 cm and right 12 cm) with diffuse peritoneal metastatic nodules were identified...
2016: Case Reports in Pathology
https://www.readbyqxmd.com/read/27803599/follow-up-of-patients-who-are-clinically-disease-free-after-primary-treatment-for-fallopian-tube-primary-peritoneal-or-epithelial-ovarian-cancer-a-program-in-evidence-based-care-guideline-adaptation
#17
T Le, E B Kennedy, J Dodge, L Elit
BACKGROUND: A need for follow-up recommendations for survivors of fallopian tube, primary peritoneal, or epithelial ovarian cancer after completion of primary treatment was identified by Cancer Care Ontario's Program in Evidence-Based Care. METHODS: We searched for existing guidelines, conducted a systematic review (medline, embase, and cdsr, January 2010 to March 2015), created draft recommendations, and completed a comprehensive review process. Outcomes included overall survival, quality of life, and patient preferences...
October 2016: Current Oncology
https://www.readbyqxmd.com/read/27801755/the-fallopian-tube-origin-and-primary-site-assignment-in-extrauterine-high-grade-serous-carcinoma-findings-of-a-survey-of-pathologists-and-clinicians
#18
W Glenn McCluggage, Lynn Hirschowitz, C Blake Gilks, Nafisa Wilkinson, Naveena Singh
Accumulating recent evidence suggests that the majority of extrauterine high-grade serous carcinomas (HGSCs) do not arise from the ovary as historically accepted but from the distal, fimbrial end of the fallopian tube from a precursor known as serous tubal intraepithelial carcinoma. There has been variable acceptance of this evidence among pathologists and clinicians dealing with "ovarian" cancer and this has resulted in wide variation in the assignment of primary site between different institutions when HGSC involves >1 anatomic site...
October 31, 2016: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/27801734/pd-l1-expression-in-carcinosarcomas-of-the-gynecologic-tract-a-potentially-actionable-biomarker
#19
Andre Pinto, Nicholas Mackrides, Mehrdad Nadji
BACKGROUND: Carcinosarcomas of the gynecologic tract, also known as malignant mixed Müllerian tumors, are aggressive neoplasms with a high recurrence rate and poor prognosis. Despite advances in adjuvant therapies in recent years, the prognosis of these tumors has not improved. In fact, there are currently no consensus guidelines for the treatment of these neoplasms and the search for targetable biomarkers has not been successful so far. Programmed death-ligand 1 (PD-L1) has emerged as a potential target for therapeutics in a number of malignant tumors, including melanoma, lung, and colorectal cancer...
October 31, 2016: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/27794568/bevacizumab-in-ovarian-cancer-state-of-the-art-and-unanswered-questions
#20
Angela Musella, Laura Vertechy, Alessia Romito, Claudia Marchetti, Andrea Giannini, Valentina Sciuga, Carlotta Bracchi, Federica Tomao, Violante Di Donato, Francesca De Felice, Marco Monti, Ludovico Muzii, Pierluigi Benedetti Panici
Ovarian cancer is a most lethal gynecologic tumor. The mainstay treatment is cytoreductive surgery followed by platinum-based chemotherapy. However, a high percentage of patients recur, thus needing multiple treatments with a frequently poor prognosis. In the last two decades, research has focused on the potential of target therapies to improve the survival of patients affected by ovarian cancer. Bevacizumab is one of the most studied target therapies, and it is approved for first- and second-line treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal tumors...
October 29, 2016: Chemotherapy
keyword
keyword
43221
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"